NASDAQ
26.12.24
21:58 Uhr
0,092 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EYENOVIA Aktie jetzt für 0€ handeln | |||||
| 09.12. | EYENOVIA, INC. - 8-K, Current Report | - | SEC Filings | ||
| 09.12. | Eyenovia Prices $1.9 Mln Registered Direct Offering | 3 | RTTNews | ||
| 06.12. | Eyenovia announces pricing of $1.9M registered direct offering | 3 | Seeking Alpha | ||
| 06.12. | Eyenovia secures $1.9 million in direct offering | 2 | Investing.com | ||
| 06.12. | Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering | 1 | GlobeNewswire (USA) | ||
| 25.11. | Eyenovia secures $1.3 million in direct offering | 1 | Investing.com | ||
| 25.11. | Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering | 1 | GlobeNewswire (USA) | ||
| 22.11. | Eyenovia secures debt payment deferral from Avenue Capital | 1 | Investing.com | ||
| 22.11. | Eyenovia sichert sich Zahlungsaufschub für Schulden von Avenue Capital | 3 | Investing.com Deutsch | ||
| 22.11. | Eyenovia, Inc.: Eyenovia Provides Update on Restructuring Efforts | 151 | GlobeNewswire (Europe) | Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic alternatives... ► Artikel lesen | |
| 20.11. | EYENOVIA, INC. - 8-K, Current Report | 7 | SEC Filings | ||
| 18.11. | Eyenovia Stock Tumbles on Termination of Phase III Myopia Study | 2 | Zacks | ||
| 15.11. | Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline | 3 | Benzinga.com | ||
| 15.11. | Eyenovia plunges as late-stage trial for myopia treatment fails | 1 | Seeking Alpha | ||
| 15.11. | Eyenovia halts myopia study after missing primary endpoint | 2 | Investing.com | ||
| 15.11. | Eyenovia, Inc.: Eyenovia Provides Update on Phase 3 CHAPERONE Study | 123 | GlobeNewswire (Europe) | A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and... ► Artikel lesen | |
| 13.11. | EYENOVIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.11. | Eyenovia GAAP EPS of -$0.11 in-line, revenue of $1.62M beats by $1.51M | 1 | Seeking Alpha | ||
| 12.11. | EYENOVIA, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.11. | EYENOVIA, INC. - 8-K, Current Report | - | SEC Filings |
Seite:
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,435 | 0,00 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,370 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 8,570 | +1,66 % | Community Rückblick: wO User zu Newron Lizenzvereinbarung mit EA Pharma: "Unheimlich guter Deal!" | © Foto: Gorodenkoff / Stock.adobe.comDie Diskussion um Newron Pharma explodierte, nachdem die italienische Biotechfirma am 13.12. die Kooperation mit "EA-Pharma" aus Japan, zum Vertrieb des Hoffnungsmittels... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,951 | +4,78 % | Nektar's NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell Lymphoma | WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) announced results of its Phase 2 proof-of-concept study, which evaluated NKTR-255 as an adjuvant treatment to enhance complete response rate... ► Artikel lesen | |
| ROCKET LAB USA | 28,440 | 0,00 % | Spotlight on Rocket Lab USA: Analyzing the Surge in Options Activity | ||
| COMPASS PATHWAYS | 4,120 | 0,00 % | Compass Pathways plc: Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added... ► Artikel lesen | |
| OPUS GENETICS | 1,070 | 0,00 % | Opus Genetics, Inc.: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| SCYNEXIS | 1,020 | 0,00 % | SCYX stock touches 52-week low at $0.97 amid market challenges | ||
| BOIRON | 26,250 | -2,42 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| LIPOCINE | 4,600 | -4,96 % | Lipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis | SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| HARROW | 35,060 | 0,00 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
| ESSA PHARMA | 1,615 | +0,31 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 | Company has initiated a process to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER... ► Artikel lesen | |
| MEDICINOVA | 1,950 | 0,00 % | MediciNova, Inc.: MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND | LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,655 | +3,84 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Anaphylm (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,181 | +4,82 % | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen |
EYENOVIA INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,092 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EYENOVIA INC finden Sie auf Wallstreet Online.
